hapabapa
- AbbVie (NYSE:ABBV) said that the US FDA has updated the indication for its JAK inhibitor Rinvoq (upadacitinib) to allow individuals with ulcerative colitis or Crohn’s disease to be given the treatment after having received at least one approved systemic therapy in